08:31 AM EDT, 03/17/2025 (MT Newswires) -- Xeris Biopharma ( XERS ) said Monday that the US Food and Drug Administration has approved the company's supplemental new drug application for Gvoke VialDx for use as a diagnostic aid to temporarily inhibit gastrointestinal tract movement during radiologic examinations in adult patients.

Xeris also said it has partnered with American Regent to commercialize Gvoke VialDx in the US.

Xeris said it would handle product supply while American Regent would oversee commercialization.

Financial terms of the agreement were not disclosed.